• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    4/22/25 7:00:09 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QNTM alert in real time by email
    6-K 1 f6k_042225.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2025

    Commission File Number: 001-39152

    Quantum BioPharma Ltd.
    (Translation of registrant's name into English)

    55 University Ave., Suite 1003
    Toronto, Ontario M5J2H7, Canada

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Quantum BioPharma Ltd.    
      (Registrant)
       
      
    Date: April 22, 2025     /s/ Donal Carroll    
      Donal Carroll
      Chief Financial Officer
      


    EXHIBIT INDEX

    Exhibit Number Description
       
    99.1 Press Release dated April 22, 2025

    Get the next $QNTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QNTM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000

      TORONTO, May 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $4,500,000. As previously announced the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency. This move reflects the company's belief in the potential of Bitcoin (BTC) and other currencies to prov

      5/19/25 7:30:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference

      TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) "Quantum BioPharma" or the "Company") a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management will attend the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025. Quantum BioPharma Head of Finance and M&A Jason Sawyer will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22, where Mr. Sawyer is scheduled to host one-on-one meetings with institutional investors at both events and host a webcast presentation at the Sidoti Mi

      5/16/25 7:30:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

      TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS) for Multiple Sclerosis ("MS"). These studies were commissioned to provide data to support an IND application with the US FDA. "We are very pleased to have completed dosing in these toxicity studies as this advances the Lucid-21-302 drug development program," said Dr. Andrzej Chruscinski, Vice-President, Scientific and C

      5/12/25 8:00:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QNTM
    SEC Filings

    See more
    • SEC Form 6-K filed by Quantum Biopharma Ltd.

      6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

      5/19/25 7:30:04 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Quantum Biopharma Ltd.

      6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

      5/16/25 7:30:04 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Quantum Biopharma Ltd.

      6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

      5/14/25 4:30:46 PM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QNTM
    Financials

    Live finance-specific insights

    See more
    • Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time

      TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) "Quantum BioPharma" or the "Company"), today announced it will host a Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern time to discuss its recent year-end financial results, regulatory initiatives, commercial-readiness activities and anticipated milestones. Quantum BioPharma CEO, President, & Executive Co-Chair Zeeshan Saeed and Head of Finance and M&A Jason Sawyer will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the

      4/24/25 7:00:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

      TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of MZHCI, LLC, an MZ Group Company ("MZ"), to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ will work closely with Quantum BioPharma management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlig

      2/11/25 7:30:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QNTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

      TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management. About Mr. Kevin Malone Mr. Malone is a 2nd generation financial advisor with over 40 years of family experience in wealth management. This combined with his deep entrepreneurial background he launched Malone Wealth in 2021. Mr. Malone focuses deeply on pattern recognition skills and data research to diffe

      4/22/25 7:00:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors

      TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company. Mr. Terry Lynch Mr. Lynch is widely known and respected for his role founding and operating Save Canadian Mining, a not-for-profit organization leading the fight against micro-cap stock market manipulation and naked short selling. Mr. Lynch has a long,

      3/27/25 7:00:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

      TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the e

      11/25/24 7:00:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care